Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 291 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Auto Plus Clear all
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

NCT03589885
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up

NCT00697047
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Automated Mailing, Automated Mailing Plus Assisted, Auto Plus Assisted Plus Navigation
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 73 Years
Enrollment
4,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

NCT02023879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

NCT02059291
View directory record Official record
Conditions
Hereditary Periodic Fevers
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 6, 2026, 5:50 AM EDT
Terminated Not applicable Interventional

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

NCT03717142
View directory record Official record
Conditions
Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02338960
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Bremelanotide, Placebo
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

NCT05032820
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, bb2121, Cyclophosphamide, Fludarabine, leukapheresis
Drug · Biological · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Distracted Driving App Study for Teens and Parents/Caregivers

NCT04177524
View directory record Official record
Conditions
Distracted Driving
Interventions
Background Mode, Manual Mode, Auto-Detect Mode
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
16 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

NCT00319501
View directory record Official record
Conditions
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
86
States / cities
Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 6, 2026, 5:50 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Kosmos Guidance Performance Evaluation Data Annotation

NCT07771270
View directory record Official record
Conditions
Heart, Ultrasound, Cardiac Ultrasound, Cardiac Disease
Interventions
Category 1: Corrective Guidance, Category 2: Incorrect Scanning Window, Category 3: Incorrect Probe Orientation, Category 4: Low Confidence Prediction, Auto-Capture Frame-Level Re-Annotation
Device
Lead sponsor
EchoNous Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 6, 2026, 5:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Auto Transplantation of Wisdom Teeth

NCT06553300
View directory record Official record
Conditions
Autotransplantation of Wisdom Teeth, Patelet Rich Fibrin
Interventions
Autotransplantation with PRF, Autotransplatation Only
Procedure
Lead sponsor
Cleveland Dental Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

NCT00002548
View directory record Official record
Conditions
Multiple Myeloma
Interventions
recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 70 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
34
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

NCT01392625
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
Autologous hMSCs, Allogeneic hMSCs
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

NCT02614287
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00425321
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
RWJ-445380 100 mg, RWJ-445380 200 mg, RWJ-445380 300 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Not applicable Interventional Results available

Comparison of Breathing Event Detection by a Continuous Positive Airway Pressure Device to Clinical Polysomnography

NCT00836758
View directory record Official record
Conditions
Sleep Apnea
Interventions
Analysis with AED and manual PSG scoring
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

NCT03383055
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma
Interventions
CMV-MVA Triplex Vaccine
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Early Phase 1 Interventional

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

NCT00314743
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ondansetron, Dexamethasone, Aprepitant
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Positive Pressure Treatment of Obstructive Sleep Apnea

NCT00636181
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Auto AFlex, Auto CPAP, CPAP
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

NCT02656069
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
6
States / cities
Birmingham, Alabama • Chula Vista, California • Escondido, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 6, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

NCT00976937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Sep 6, 2026, 5:50 AM EDT
Active, not recruiting Not applicable Interventional

Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

NCT04922307
View directory record Official record
Conditions
Kidney Cancer
Interventions
Blood Sparing Protocol, Standard Blood Replacement
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 6, 2026, 5:50 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

NCT06841575
View directory record Official record
Conditions
Eye Diseases, Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions
Auto-aligned OCT
Device
Lead sponsor
Duke University
Other
Eligibility
1 Month and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 6, 2026, 5:50 AM EDT